A study to demonstrate that a novel, light based, imaging system could be used in neurosurgical procedures in the future with a view to improving outcomes
Hyperspectral imaging systems allow us to interpret bands of light beyond what the naked eye can see. It has already been used to great effect in other industries and has begun to show some promise within clinical practice. Our novel system employs this technology into the neurosurgical theatre with the expectation that it will be able to provide valuable, live information to the surgeon allowing them to carry out safer operations for our patients.
The purpose of this study is to assess the quality of data obtained by our system and how well it integrates into current neurosurgical practice. We are currently running a public engagement group that had its first meeting on 9th February 2022, providing valuable to our research team on this study.
We plan to meet 6 monthly to annually. If this is something you would like to be involved in please use the contact form. Similarly, if you would like more information about what the study entails from a patient perspective, please take a look at our study pamphlet and our patient information sheets (PIS):
Alternatively, feel free to contact us and one of the research team will get back to you.
We are actively involving patients and carers to make our research on next generation neurosurgery more relevant and impactful. Early February 2022, our research scientists from King’s College London and King’s College Hospital organised a Patient and Public Involvement (PPI) meeting with support from The Brain Tumour Charity.
Post overview: Focus: Translational research on real-time computing for hyperspectral imaging linked with an active neurosurgery clinical study Line manager: Tom Vercauteren Industry collaborator: Hypervision Surgical Clinical collaborator: King’s College Hospital Salary: Grade 6, £38,826 - £45,649 per annum, including London Weighting Allowance Hyperspectral Imaging (HSI) in the operating room.
A consortium of researchers, clinicians, and industry partners have received an NIHR invention for innovation (i4i) product development award to support a clinical neurosurgery study and quality management system led product development for an intraoperative hyperspectral imaging (HSI) technology, designed to make brain tumour removal surgery safer and more complete.
Brain surgery operations include brain tumour removal and blood vessel procedures. Each year in the UK, approximately 70,500 patients are diagnosed with a brain tumour, 5,000 of whom undergo surgery. Approximately 1,000 patients undergo blood vessel brain surgery. Brain tumour surgery involves removing as much of the tumour as safely as possible. If all tumour is removed, patients have significantly better outcomes and live longer.
However, even with the best hands and the most modern technology currently available, it is often not possible to reliably identify tumour during surgery. Moreover, nerves and blood vessels cannot be reliably identified either during surgery. Yet, they need to be preserved to avoid brain damage. Due to this uncertainty and the need to balance risks, tumour is often left behind. Today, close to 30% of brain tumour patients require repeat surgery owing to tumour left behind during their first surgery. Further surgeries are more difficult, pose additional patient risks and lead to increased healthcare costs with often poor patient outcomes.
Newly developed camera systems have the potential to enhance the surgeon s vision to reliably identify tumour and healthy brain structures. Hyperspectral imaging (HSI) is one of the most promising of such technologies. Its core ability is to provide very detailed and rich information that is invisible to the human eye. HSI has demonstrated the potential to provide crucial, but currently unavailable, information about tumour and critical brain structures during surgery. However, HSI data is very complex and requires advanced computer-processing for its interpretation. In two previous clinical studies, we have shown that we can safely integrate our HSI prototype system during surgery.
In this project, we will further advance our prototype, refine our setup and develop key computer-processing features. We will assess our system in a new clinical study involving 81 patients undergoing brain tumour and blood vessel surgery. The outcomes of this study will inform the commercialisation of the technology for patient and NHS benefits.
This study has been designed with patient input and feedback from various patient groups including The Brain Tumour Charity. We received feedback stating that this research in improving surgical outcomes is potentially life-changing, drastically improving patient health, wellbeing and quality of life. The study will form a Patient Advisory Group to advise on all stages of the research. A patient representative, named public co-applicant on the project team, will sit on the study management board. We will ensure that the patient voice is expressed clearly in study reports and when sharing research updates more widely. Results will be made publicly available through publication of open-access research papers, presentation of results at scientific meetings, patient events, and online via King’s College London and relevant charity websites/social media.
To address the pressing clinical need of improved surgical precision and patient safety during neurosurgery, we will develop a medical device capable of contact-free, contrast-agent-free, wide-field imaging and real-time tissue characterisation for seamless surgical guidance. Our innovation relies on advancing data-driven hyperspectral imaging (HSI).
Even though the ability of HSI to differentiate tissue types and measure tissue characteristics is supported by a relatively large body of scientific evidence, to date, commercial HSI systems are used mainly for tissue healing analysis rather than for surgical guidance. Indeed, existing systems are slow (20s per image) and lack sterility features vital for surgical guidance.
This project builds on our previous research with two successful first-in-patient studies demonstrating that our initial intraoperative HSI (iHSI) prototype seamlessly integrates into the surgical workflow. To deliver on this primary objective, our project will pursue eight aims for our iHSI technology:
Our project plan, executed within a 36-month period, is divided into five work packages (WPs) spanning:
The close collaboration between King’s College London, King’s College Hospital and Hypervision Surgical Ltd (King’s spin-out) will ensure a fast-tracked conversion from a healthcare innovation into a product achieving accelerated patient and public benefit. By the end of the project, our technology will be ready for MHRA submission and for inclusion in prospective clinical efficacy studies.